Protection by design
MEVOX combines in-house expertise with world class partnerships in antigen design and disease. We leverage this translational expertise and cutting-edge vaccine innovation to bring established vaccines into the 21st century and address significant unmet needs.
Who is MEVOX ?
MEVOX brings vaccinology into the 21st century. We translate cutting-edge molecular characterization, design and engineering into conformationally precise and optimized protein antigens. These induce 10-100 times higher neutralising antibody levels than existing vaccines. We embed this scientific excellence in partnerships with world leaders on our target diseases and antigen characterization and design. Our goal is global health impact through protection by design.
Executives
Board
Executives
Mike Watson and Guillaume Stewart-Jones
are the executives of Mevox ltd.
Mike Watson
CEO
Guillaume Stewart-Jones
Chief Scientific Officer
and our investors
Our Values
Vaccine Architects Engineering
Protection by design
Protection by design
Cutting Edge Science
We apply atomic level antigen characterization, structure-based design and engineering to optimize immunogenicity, safety, producibility and access.
Synergy
We partner with world class expertise and synergize the best both internally and externally.
Equitable Access
We minimize barriers to access, whether they be stability, price, or scale.
Impact
We want to unleash human potential by removing the burden of infectious disease.
Energy
What’s not energizing about making lives better, working with great people and great science?